{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:47Z","timestamp":1787026667903,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary fibrosis is a fatal disease characterized by progressive scarring of lung tissue, with a complex pathogenesis and limited therapeutic options. The identification of robust biomarkers is critical for addressing key clinical challenges, including delayed diagnosis and poor prognostic assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study systematically analyzes global research trends and emerging hotspots in pulmonary fibrosis biomarkers by examining literature from 2001 to 2024 indexed in the Web of Science Core Collection. Utilizing a suite of bibliometric tools including VOSviewer, CiteSpace, Bibliometrix, Scimago Graphica, and OriginPro 2021, this work provides the first comprehensive insight into the evolving landscape of biomarker research in pulmonary fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included a total of 2,519 articles and reviews related to pulmonary fibrosis biomarkers. Since 2005, publication trends in this field have steadily increased. Research on pulmonary fibrosis biomarkers has involved 71 countries, 3,036 institutions, 760 journals, and over 14,000 researchers. China produced the highest number of publications (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f535, 21.2%, TLCS\u202f=\u202f459), followed by the United States (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f529, 21%, TLCS\u202f=\u202f3,527) and Japan (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f270, 10.7%, TLCS\u202f=\u202f1,279), with the United States exerting the greatest influence. The UNIVERSITY OF CALIFORNIA SYSTEM (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f164) and HARVARD UNIVERSITY (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f141) contributed the largest bodies of work. The most prolific authors in this domain are BARGAGLI E (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f45), MAHER TM (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f42), and MARTINEZ FJ (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f32). The AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE is widely regarded as the leading journal in this field. In recent years, research has increasingly focused on macrophages, computed tomography, and Muc5b promoter polymorphism, among other areas. The concept of \u201cdouble blind\u201d reflects the translational trend of biomarkers toward clinical applications, particularly their potential utility in acute exacerbations of pulmonary fibrosis, interstitial pulmonary fibrosis, cystic pulmonary fibrosis, and radiation-induced pulmonary fibrosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The clinical application of gene and imaging biomarkers achieved through the integration of multiple parameters and multi-omics fusion represents a promising future trend and emerging hotspot in pulmonary fibrosis biomarker research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1541364","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:10:45Z","timestamp":1745539845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Trends and hotspots in pulmonary fibrosis biomarker research: a bibliometric analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fmed.2024.1384825","article-title":"Editorial: epidemiology and risk factors for interstitial lung diseases","volume":"11","author":"Jeganathan","year":"2024","journal-title":"Front Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/thorax-2024-221581","article-title":"Epidemiology of idiopathic pulmonary fibrosis: opportunities and hurdles for population-level studies of rare disease","volume":"79","author":"Marinescu","year":"2024","journal-title":"Thorax"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1601504","DOI":"10.1183\/13993003.01504-2016","article-title":"Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada","volume":"49","author":"Harari","year":"2017","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.prp.2023.154691","article-title":"Cellular mechanisms in the pathogenesis of interstitial lung diseases","volume":"248","author":"Singh","year":"2023","journal-title":"Pathol Res Pract"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2169\/internalmedicine.56.8065","article-title":"Colitis associated with Nintedanib therapy for idiopathic pulmonary fibrosis (IPF)","volume":"56","author":"Oda","year":"2017","journal-title":"Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/1346-8138.13009","article-title":"Pirfenidone-induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis","volume":"43","author":"Tsuruta","year":"2016","journal-title":"J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7326\/0003-4819-89-4-459","article-title":"Bronchoalveolar lavage in interstitial lung disease","volume":"89","author":"Weinberger","year":"1978","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1336666","DOI":"10.3389\/fimmu.2024.1336666","article-title":"Global research trends on innate lymphoid cells in the brain, gut and lung field: a bibliometric and visualized analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3390\/ijms18122527","article-title":"Role of MicroRNAs in TGF-\u03b2 signaling pathway-mediated pulmonary fibrosis","volume":"18","author":"Kang","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13023-021-01750-3","article-title":"Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF","volume":"16","author":"Bonella","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref11","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annual Symposium proceedings AMIA Symposium"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2101612","DOI":"10.1183\/13993003.01612-2021","article-title":"A systematic review and individual participant data meta-analysis of MMP-7 and outcomes in idiopathic pulmonary fibrosis","volume":"59","author":"Khan","year":"2021","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.26442\/terarkh201890342-46","article-title":"Clinical significance of the determination of surfactant proteins a and D in assessing the activity of lung sarcoidosis","volume":"90","author":"Beketov","year":"2018","journal-title":"Ter Arkh"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur Respir J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000196393","article-title":"Aberrant appearance of lung surfactant protein a in sera of patients with idiopathic pulmonary fibrosis and its clinical significance","volume":"62","author":"Honda","year":"1995","journal-title":"Respiration; Int Rev Thoracic Dis"},{"key":"ref17","first-page":"5497","article-title":"Clinical characteristics and serum levels of tumor markers of connective tissue disease-associated interstitial lung disease","volume":"12","author":"Shen","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.chest.2021.06.067","article-title":"Clinical significance of cold-inducible RNA-binding protein in idiopathic pulmonary fibrosis","volume":"160","author":"Hozumi","year":"2021","journal-title":"Chest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1164\/rccm.201509-1789ED","article-title":"Personalizing therapy in idiopathic pulmonary fibrosis: a glimpse of the future?","volume":"192","author":"Kropski","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1164\/rccm.201601-0055ED","article-title":"The airway in idiopathic pulmonary fibrosis: protecting the lung or promoting disease?","volume":"193","author":"Ryu","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"102334","DOI":"10.1016\/j.pupt.2024.102334","article-title":"ALDH2 attenuates radiation-induced lung injury by inhibiting ROS and epithelial-mesenchymal transition mediated by the TGF-\u03b21\/Smad pathway","volume":"87","author":"Li","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/cells13181523","article-title":"Bleomycin-induced pulmonary fibrosis in transgenic mice carrying the human MUC5B rs35705950 variant","volume":"13","author":"Tharavecharak","year":"2024","journal-title":"Cells"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.3390\/jcm13206159","article-title":"MUC5B rs35705950 promoter variant is associated with usual interstitial pneumonia in patients with Antisynthetase syndrome","volume":"13","author":"Rivero-Gallegos","year":"2024","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/ahg.12522","article-title":"Reassessing the association of MUC5B with survival in idiopathic pulmonary fibrosis","volume":"87","author":"Cai","year":"2023","journal-title":"Ann Hum Genet"},{"key":"ref25","first-page":"10.1136\/jim-2017-000663.426","article-title":"Expression of muc5b and markers of endoplasmic reticulum stress are jointly expressed in idiopathic pulmonary fibrosis","volume":"66","author":"Schulick","year":"2018","journal-title":"J Investig Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/thoraxjnl-2012-202957","article-title":"MUC5B: a good target for future therapy in pulmonary fibrosis?","volume":"68","author":"Mahida","year":"2013","journal-title":"Thorax"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1056\/NEJMc1105707","article-title":"MUC5B promoter polymorphism and pulmonary fibrosis","volume":"365","author":"Zhang","year":"2011","journal-title":"N Engl J Med"},{"key":"ref28","first-page":"14953","article-title":"Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis","volume":"8","author":"Jiang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/thoraxjnl-2020-214579","article-title":"Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?","volume":"75","author":"Stock","year":"2020","journal-title":"Thorax"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/thoraxjnl-2019-214061","article-title":"MUC5B promoter variant: genomic fingerprint for early identification of undiagnosed pulmonary fibrosis","volume":"74","author":"Adegunsoye","year":"2019","journal-title":"Thorax"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/resp.12569","article-title":"Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers","volume":"20","author":"Hambly","year":"2015","journal-title":"Respirology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MCP.0b013e328363f4b7","article-title":"Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine","volume":"19","author":"Maher","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1164\/rccm.202110-2296OC","article-title":"The proteomic profile of interstitial lung abnormalities","volume":"206","author":"Axelsson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12931-023-02424-3","article-title":"Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis","volume":"24","author":"She","year":"2023","journal-title":"Respir Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fimmu.2022.923235","article-title":"The emerging roles of interstitial macrophages in pulmonary fibrosis: a perspective from scRNA-seq analyses","volume":"13","author":"Gu","year":"2022","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/jat.4612","article-title":"The multifaceted role of macrophage mitophagy in SiO<sub>2<\/sub>\u2212induced pulmonary fibrosis: a brief review","volume":"44","author":"Zhou","year":"2024","journal-title":"J Appl Toxicol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mtbio.2023.100653","article-title":"Novel strategy of combined interstitial macrophage depletion with intravenous targeted therapy to ameliorate pulmonary fibrosis","volume":"20","author":"Li","year":"2023","journal-title":"Materials Today Bio"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s11427-022-2314-8","article-title":"Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization","volume":"66","author":"Yan","year":"2023","journal-title":"Sci China-Life Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1165\/rcmb.2013-0386OC","article-title":"Tumor necrosis factor-\u03b1 accelerates the resolution of established pulmonary fibrosis in mice by targeting Profibrotic lung macrophages","volume":"50","author":"Redente","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms231911443","article-title":"Plasticity towards rigidity: a macrophage conundrum in pulmonary fibrosis","volume":"23","author":"Sari","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.3390\/jcm12155136","article-title":"MRI and pulmonary function Tests' results as ventilation inhomogeneity markers in children and adolescents with cystic fibrosis","volume":"12","author":"Wojsyk-Banaszak","year":"2023","journal-title":"J Clin Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/thoraxjnl-2016-209831","article-title":"Diagnosing idiopathic pulmonary fibrosis without a lung biopsy: honeycombing not required","volume":"72","author":"Homer","year":"2017","journal-title":"Thorax"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e2329119","DOI":"10.2214\/AJR.23.29119","article-title":"Imaging of pulmonary fibrosis: an update, from theAJRSpecial series on imaging of fibrosis","volume":"222","author":"Lee","year":"2024","journal-title":"Am J Roentgenol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2214\/AJR.14.12461","article-title":"Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis","volume":"204","author":"Valeur","year":"2015","journal-title":"Am J Roentgenol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2214\/AJR.15.15674","article-title":"CT in idiopathic pulmonary fibrosis: diagnosis and beyond","volume":"206","author":"Gruden","year":"2016","journal-title":"Am J Roentgenol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2478\/jtim-2023-0114","article-title":"Cardiac magnetic resonance imaging-derived septum swing index detects pulmonary hypertension: a diagnostic study","volume":"11","author":"He","year":"2023","journal-title":"J Translational Internal Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1378\/chest.120.1_suppl.S68","article-title":"Circulating transforming growth factor-beta(1): a potential marker of disease activity during idiopathic pulmonary fibrosis","volume":"120","author":"Yong","year":"2001","journal-title":"Chest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00408-021-00490-2","article-title":"Prognostic significance of pulmonary artery to aorta ratio and other CT markers in pulmonary fibrosis with and without emphysema","volume":"199","author":"Zeba","year":"2021","journal-title":"Lung"},{"key":"ref49","first-page":"788","article-title":"Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?","volume":"23","author":"Gordon","year":"1996","journal-title":"J Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijms232314959","article-title":"Pulmonary fibrosis as a result of acute lung inflammation: molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches","volume":"23","author":"Savin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/arm91010005","article-title":"Cellular and molecular mechanisms in idiopathic pulmonary fibrosis","volume":"91","author":"Zhang","year":"2023","journal-title":"Advan Respiratory Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1541364\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:10:46Z","timestamp":1745539846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1541364\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":51,"alternative-id":["10.3389\/fmed.2025.1541364"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1541364","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1541364"}}